Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC70 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 9501.026 | uM | 7.09240 | 7.60970 | 0.4779 | -0.2089 | 4.9603 | 0.0540 | 0.7273 | 0.7616 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 9664.124 | uM | inf | inf | 0.9407 | 0.9407 | 0.0000 | -0.0184 | 0.0798 | 0.8433 | |
MDA-MB-453 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 7903.042 | uM | inf | inf | 0.9956 | 0.9956 | 0.0000 | -0.0024 | -0.0113 | 1.1508 | |
HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7811.018 | uM | inf | inf | 0.6946 | 0.6946 | 0.0000 | 0.1308 | -0.0060 | 0.4694 | |
HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7812.042 | uM | inf | inf | 0.5614 | 0.5614 | 0.0000 | 0.0267 | 0.3674 | 0.9722 | |
AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 9146.122 | uM | inf | inf | 0.9694 | 0.9694 | 0.0000 | -0.0404 | -1.9847 | 1.3408 | |
MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7897.018 | uM | inf | inf | 0.8611 | 0.8611 | 0.0000 | 0.0755 | -0.1097 | 0.8448 | |
AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7793.018 | uM | inf | inf | 0.9318 | 0.9318 | 0.0000 | 0.0067 | 0.3477 | 1.3186 | |
AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 9035.018 | uM | inf | inf | 0.9083 | 0.9083 | 0.0000 | 0.0297 | 0.4162 | 2.1555 | |
AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7794.018 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 1.6812 | |
MDA-MB-134-VI | HR+ | Luminal | Trastuzumab | HER2 | ErbB | 10077.026 | uM | 7.0350 | 7.93710 | 0.4622 | -0.4084 | 4.9480 | -0.0133 | 0.9348 | 0.3999 | |
MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 9583.026 | uM | inf | inf | 0.9966 | 0.9966 | 0.0000 | 0.0156 | -0.0344 | 1.2731 | |
MCF 10F | NM | - | Pertuzumab | 7487.102 | mg/ml | inf | 124.94960 | 0.6533 | -0.1750 | 0.2135 | 0.1284 | 0.7894 | 1.5273 | |||
MCF 10A | NM | Basal B | Cetuximab | EGFR | ErbB | 7870.018 | uM | 0.39912 | 0.12872 | 0.4513 | 0.4038 | 1.4562 | 0.0600 | 0.9769 | 2.2478 | |
MCF 10A | NM | Basal B | Cetuximab | EGFR | ErbB | 9551.026 | uM | inf | 0.14350 | 0.7282 | 0.7281 | 4.9914 | 0.0090 | 0.9280 | 2.6508 | |
MCF 10F | NM | - | Trastuzumab | HER2 | ErbB | 9566.026 | uM | inf | inf | 0.9681 | 0.9681 | 0.0000 | -0.0233 | -0.7310 | 2.1367 | |
HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 9501.026 | uM | inf | 0.01283 | 0.4925 | 0.5840 | 1.2619 | 0.0978 | 0.8957 | 0.7616 | |
HMT-3522 S1 | Unknown | Unknown | Cetuximab | EGFR | ErbB | 7911.018 | uM | 0.02673 | 0.01835 | 0.1964 | 0.1241 | 0.7579 | 0.2589 | 0.9901 | 1.8543 | |
HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 10268.122 | uM | 3.49450 | 1.70630 | 0.4865 | 0.4861 | 4.9935 | 0.0343 | 0.6574 | 0.6345 | |
MCF7 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 7874.018 | uM | inf | inf | 0.9611 | 0.9611 | 0.0000 | -0.0261 | -0.1994 | 1.6506 | |
HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7860.042 | uM | 1.41750 | 6.04060 | 0.6742 | -0.9996 | 0.7577 | 0.0164 | 0.8799 | 0.6736 | |
SUM185PE | TNBC | Luminal | Cetuximab | EGFR | ErbB | 7921.042 | uM | inf | inf | 1.0399 | 1.0399 | 0.0000 | -0.0494 | -236.5755 | 0.6355 | |
SUM185PE | TNBC | Luminal | Cetuximab | EGFR | ErbB | 10146.124 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0500 | -inf | 0.9296 | |
HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7857.042 | uM | inf | 0.00139 | 0.7456 | 0.7944 | 5.0000 | 0.1040 | 0.8457 | 1.1910 | |
HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7856.018 | uM | inf | inf | 0.8811 | 0.8811 | 0.0000 | 0.0121 | 0.4683 | 0.9388 |